Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 84Sarcoma 17Tumor-Agnostic 14CNS 7Genitourinary 5Thoracic 3Gynecologic 3Other solid neoplasm 2Other hematologic neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Thymoma 1Sarcoma 1Pancreatic Neoplasms 1Melanoma 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × regorafenib × Gynecologic × Clear all
NCT02584465 2023-09-06

REGOVAR

ARCAGY/ GINECO GROUP

Phase 2 Completed
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT02307500 2022-09-10

RESOUND

Istituto Clinico Humanitas

Phase 2 Completed
82 enrolled
DermatologicGastrointestinalGynecologicSarcomaThoracic

Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Thymoma

NCT02736305 2022-06-13

Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

National Cancer Centre, Singapore

Phase 2 Completed
21 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡